Aptamer-target interaction descriptor
Aptamer-target interaction information
Interaction ID: 673
Aptamer sequence: GACCAGGGCAAACGGTAGGGAGTGGTC
Target unique ID: 6322
Aptamer ID Aptamer descriptor Target chemistry Target name Affinity Binding Conditions/Buffer PubMed ID
Apta_630 Dec-79 Molecule Arginine 2.5 mM 10 mM sodium phosphate buffer (pH 7.5) and 100 mM NaCl 8846773
Structure information of aptamer
Aptamer Sequence: GACCAGGGCAAACGGTAGGGAGTGGTC
The optimal secondary structure in dot-bracket notation: (((((.................)))))
The centroid secondary structure in dot-bracket notation: (((((.................)))))
The MFE structure
The Centroid structure
The mountain plot representation
Aptamer information
Type Detail Type Detail
Aptamer ID Apta_630 Description Dec-79
Aptamer chemistry DNA Length 27 nt
GC content 63.0% Molecular weight 8,439.44 Da
Molarity of 1 μg/μl solution 118.49 μM Number of G-quadruplexes 2
G-Score 19 Function Targeted binding
Sequence GACCAGGGCAAACGGTAGGGAGTGGTC
Applications Binding to arginine
Target information
Type Detail Type Detail
PubChem ID 6322 Molecular name Arginine
Molecular formula C6H14N4O2 Molecular weight 174.2
IUPAC name (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid InChIKey ODKSFYDXXFIFQN-BYPYZUCNSA-N
LogP -1.548 Topological polar surface area 127.72
Hydrogen bond acceptor 3 Hydrogen bond donor 4

Synonym(s):
L-arginine; arginine; 74-79-3; L-(+)-Arginine; L(+)-Arginine; L-Arg; (S)-2-Amino-5-guanidinopentanoic acid; H-Arg-OH; (L)-Arginine; Arginina; ARGININE, L-; Arginine (VAN); L-Arginin; Argininum [INN-Latin]; Arginina [INN-Spanish]; L-Ornithine, N5-(aminoiminomethyl)-; Argamine; Argivene; Detoxargin; Levargin; L-alpha-Amino-delta-guanidinovaleric acid; Minophagen A; 1-Amino-4-guanidovaleric acid; CCRIS 3609; (S)-(+)-arginine; NSC 206269; arg; HSDB 1429; AI3-24165; UNII-94ZLA3W45F; (S)-2-Amino-5-guanidinovaleric acid; BRN 1725413; CHEBI:16467; (S)-2-Amino-5-((aminoiminomethyl)amino)pentanoic acid; L-Norvaline, 5-((aminoiminomethyl)amino)-; MFCD00002635; 2-amino-5-guanidinovaleric acid; CHEMBL1485; (2S)-2-amino-5-guanidinopentanoic acid; (S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid; 94ZLA3W45F; Pentanoic acid, 2-amino-5-((aminoiminomethyl)amino)-, (S)-; (2S)-2-amino-5-(carbamimidamido)pentanoic acid; L-Arginine, monohydrochloride; Arginine (L-Arginine); R-Gene; L-Norvaline, 5-[(aminoiminomethyl)amino]-; (2S)-2-amino-5-carbamimidamidopentanoic acid; DSSTox_CID_21056; DSSTox_RID_79618; DSSTox_GSID_41056; C6H14N4O2; Argininum; Pentanoic acid, 2-amino-5-[(aminoiminomethyl)amino]-, (S)-; Arginine [USAN:INN]; (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid; CAS-74-79-3; Arginine [USP:INN]; EINECS 200-811-1; 2-AMINO-5-GUANIDINO-PENTANOIC ACID; NSC203450; 3h-l-arginine; L-Arginine, labeled with tritium; 1laf; NSC-206269; L-a-Amino-d-guanidinovaleric acid; NCGC00015064-02; (S)-Arginine; L(+) arginine; L-Aryginine,(S); H-Arg; L-(+) arginine; L(+)-Arginine;; L-Arginine (9CI); Arginine (USP/INN); Tocris-0663; (2S)-2-amino-5-guanidino-pentanoic acid; L-Arginine (JP17); GND; Lopac-A-5006; Arginine, L- (8CI); bmse000029; bmse000899; bmse000919; Epitope ID:140084; L-Arginine (H-Arg-OH); EC 200-811-1; SCHEMBL1791; 2-amino-5-guanidinovalerate; Lopac0_000077; Arginine hydrochloride(USAN); GTPL721; 4-04-00-02648 (Beilstein Handbook Reference); L-a-Amino-d-guanidinovalerate; L-Amino-4-guanidovaleric acid; US9138393, L-Arginine; US9144538, L-Arginine; 1-Amino-4-guanidovalerlic acid; DTXSID6041056; BDBM21959; L-Arginine, 99%, FCC, FG; BDBM181132; HMS3260O15; N5-(aminoiminomethyl)-L-Ornithine; HY-N0455; ZINC1532525; L-Arginine, Vetec(TM), 98.5%; Tox21_113046; Tox21_500077; AC-083; L-2-Amino-5-guanidinopentanoic acid; L-alpha-Amino-delta-guanidinovalerate; L-Arginine, reagent grade, >=98%; s5634; AKOS006239069; AKOS015854096; Tox21_113046_1; AM81500; CCG-204172; DB00125; LP00077; MCULE-5108123240; SDCCGSBI-0050065.P002; L-Arginine, 99%, natural, FCC, FG; (s)-2-amino-5-guanidino-pentanoic acid; 5-[(aminoiminomethyl)amino]-L-Norvaline; NCGC00015064-01; NCGC00024715-01; NCGC00024715-02; NCGC00024715-03; NCGC00024715-04; NCGC00024715-05; NCGC00024715-10; NCGC00260762-01; 4455-52-1; AS-14190; K277; L-Arginine, BioUltra, >=99.5% (NT); SBI-0207062.P001; AB0014136; A0526; A7079; EU-0100077; L-Arginine, SAJ special grade, >=98.0%; A 5006; C00062; D02982; L-Arginine, Vetec(TM) reagent grade, >=98%; M02981; 14932-EP2316830A2; 2-azaniumyl-5-(diaminomethyleneammonio)pentanoate; AB00374192_03; Norvaline, 5-[(aminoiminomethyl)amino]-, (L)-; 002A635; A837397; A929348; Q173670; SR-01000075479; SR-01000597671; (S)-2-amino-5-[(aminoiminomethyl)amino]-Pentanoate; (S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoate; SR-01000075479-1; SR-01000597671-1; W-104410; (S)-2-amino-5-[(aminoiminomethyl)amino]-Pentanoic acid; Arginine, European Pharmacopoeia (EP) Reference Standard; (2S)-2-amino-5-[(diaminomethylidene)amino]pentanoic acid; 7F15B0C7-356D-45D7-AC33-03AEE4394A0E; S-(+)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid; UNII-0O72R8RF8A component ODKSFYDXXFIFQN-BYPYZUCNSA-N; UNII-FL26NTK3EP component ODKSFYDXXFIFQN-BYPYZUCNSA-N; (2S)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid; L-Arginine, United States Pharmacopeia (USP) Reference Standard; L-Arginine, Pharmaceutical Secondary Standard; Certified Reference Material; L-; L-Arginine, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%; L-Arginine, PharmaGrade, Ajinomoto, EP, USP, manufactured under appropriate GMP controls for Pharma or Biopharmaceutical production, suitable for cell culture

Activity data
Interaction ID 673
Target type Molecule
Target unique ID 6322
Activity 2.5 mM
Binding Conditions/Buffer

10 mM sodium phosphate buffer (pH 7.5) and 100 mM NaCl

Assay

Spectra of the isolated G-rich domain from clone 12-79 in the absence (open circles) or presence (closed circles) of 10 mM arginine

PubMed ID 8846773
Similar aptamers
Aptamer ID Aptamer chemistry Sequence Similarity
Apta_63 DNA GACCCGTGGTAGGGTAGGATGGGGTGGTC 65.52%
Apta_1024 DNA GTCCAGGGTTCCAAGGTGCTTCGTGGAC 60.71%
Apta_1204 DNA GGCACGATGTGGCTACATCGATCGCGGTACTGGTG 60.00%
Apta_1204 DNA GGCACGATGTGGCTACATCGATCGCGGTACTGGTG 60.00%
Apta_546 DNA CACGGCATGGTGGGCGTCGTG 59.26%
Apta_1200 DNA GGCACACAGGACTATACAGTGTTGCAGTGTTGCTG 57.14%
Apta_1203 DNA CCCTGCGGGGCTACCCGATATGTGTCCGAGTGGTG 57.14%
Apta_343 DNA AACAGAGGGACAAACGGGGGAAGATTTGACGTCGACGAC 56.41%
Apta_47 DNA GACCTAGCAGTGGACATGTGGCAGGGTGAAGTGGCATCGTC 56.10%
Apta_218 RNA AGCCGCGAGGGGAGGGAUAGGGUAGGGCGCGGCU 55.88%
Apta_648 DNA GCACACCGATGGCGGTCCTGTTTAGGGGGTGTGC 55.88%
Apta_66 DNA TACCGTGGTAGGGAAGGTTGGAGTGTA 55.56%
Apta_324 DNA CAAACAATCAAACAGCAGTGGGGTG 55.56%
Apta_324 DNA CAAACAATCAAACAGCAGTGGGGTG 55.56%
Apta_1039 DNA GCCCGTCCGTATGGTGGGT 55.56%
Apta_258 DNA CACTGCGGGGGTCTATACGTGAGGAAGAAGTGGGCAGGTC 55.00%
Apta_717 RNA GGCGCAGCCCGCCGAAAGGCACGUGGAACCGUC 54.55%
Apta_649 DNA GCACACCGATGGCGGTCCTGTTTAGGGGGTGTGCGTG 54.05%
Apta_371 RNA GGCAGACCAUACGGGAGAGAAACUUGCC 53.57%
Apta_419 DNA ATCAGGGCTAAAGAGTGCAGAGTTACTTAG 53.33%